| Name | Title | Contact Details |
|---|---|---|
Brittany Bradrick |
Chief Financial Officer | Profile |
Shaun Winn |
Director, Human Resources | Profile |
Shaun Winn |
Senior Director, Human Resources | Profile |
TFF Pharmaceuticals, Inc., an early-stage biopharmaceutical company focused on developing and commercializing innovative drug products for the treatment of lung diseases and conditions.
Galmed Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of Aramchol, a novel, once-daily, oral therapy for treating liver diseases utilizing its proprietary first-in-class family of synthetic fatty-acid/bile-acid conjugates, or FABACs. Aramchol is initially being developed for treating Non-Alcoholic Steato-hepatitis, or NASH, a chronic disease affecting a large population, for treating patients who also suffer from obesity and insulin resistance. Galmed Pharmaceuticals Galmed’s business has been, in its current legal structure, was incorporated in Israel on July 31, 2013 as a privately held company. However, operating since 2000 under a different group of companies established in the same year. Galmed was co-founded by Professor Tuvia Gilat and Allen Baharaff, based on Professor Gilat’s extensive research in FABAC’s and NASH.
HealthCore is a Wilmington, DE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
CANTEST Ltd is a Burnaby, BC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
PolyPeptide Labs is a world leader in the manufacture of polypeptide, custom peptide Synthesis, peptide synthesis and generic peptide : generic GMP peptide and non-GMP peptide. PolyPeptide provides global support for a quality solution.